← Eichor
Study identifier: NCT02432560 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Safety and Durability of Sirolimus for Treatment of LAM

Condition: Lymphangioleiomyomatosis  ·  Sponsor: University of Cincinnati

PhaseN/A
Planned participants600
Who can joinFemale, 18 Years to no upper limit
Healthy volunteersNo

About this study

The MIDAS study aims to follow male and female LAM patients who are currently taking, have previously failed or been intolerant of, or may (at some time in the future) take mTOR inhibitors (sirolimus or everolimus) as part of their clinical care. Adult female TSC patients may also enroll, with or without lung cysts.

This description comes directly from the study's public registry record.

Talk to the study team

Susan McMahan Sellers, BSN, RN  ·  (513) 558-4376  ·  susan.mcmahan@uc.edu

Francis X McCormack, MD  ·  (513) 558-0588  ·  frank.mccormack@uc.edu

Always discuss trial participation with your own doctor first.

Locations (20)

Stanford University Medical CenterStanford, California, United StatesRecruiting
National Jewish HealthDenver, Colorado, United StatesRecruiting
Mayo Clinic JacksonvilleJacksonville, Florida, United StatesRecruiting
Emory University School of MedicineAtlanta, Georgia, United StatesRecruiting
Loyola University Medical Center, ChicagoMaywood, Illinois, United StatesActive Not Recruiting
Brigham and Women's HospitalBoston, Massachusetts, United StatesRecruiting
University of MichiganAnn Arbor, Michigan, United StatesRecruiting
Mayo Clinic RochesterRochester, Minnesota, United StatesActive Not Recruiting
Washington University School of MedicineSt Louis, Missouri, United StatesRecruiting
University of Rochester Medical CenterRochester, New York, United StatesRecruiting
University of CincinnatiCincinnati, Ohio, United StatesActive Not Recruiting
Cleveland ClinicCleveland, Ohio, United StatesActive Not Recruiting

+ 8 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT02432560